Systematic Review and Meta-analysis of the Most Common Genetic Mutations in Esophageal Squamous Cell Carcinoma.
Esophageal cancer
Genetic mutations
Systematic review
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
26
09
2021
pubmed:
7
10
2021
medline:
5
11
2022
entrez:
6
10
2021
Statut:
ppublish
Résumé
Esophageal cancer is the second most common cancer among men and women. There is a need to systematically assess the current evidence to map out the contribution of genetic factors in the development of esophageal squamous cell carcinoma (ESCC). A literature search was carried out on published and unpublished studies up to August 2021 in Medline (PubMed), Embase (Ovid), Scopus, Proquest, Web of Science, and Google scholar. Studies that have reported the frequency of genetic mutations in ESCC were included in this study. A total of 1238 titles were retrieved through searches, and finally, 56 articles, including 8114 samples, met our predefined inclusion criteria. Of the included studies, 31 were conducted in China, 12 in Japan, and the remaining were conducted in various nations, including Brazil, Korea, and Iran. Most of our included studies evaluated the TP53 (n = 37 studies) and PIK3CA (n = 30 studies) gene mutations. TP53 (68.6%; 95% CI: 61.6-74.9), CCND1 (39.3%; 95% CI: 26.2-54.1), MDM2 (24.9%; 95% CI: 9.5-51.0), NOTCH1/2/3 (17.9%; 95% CI: 15.0-21.2), KMT2D (17.4%; 95% CI: 12.4-23.8), CDKN2A (15.0%; 95% CI: 8.1-26.1), PIK3CA (13.8%; 95% CI: 10.3-18.1), FAT1 (13.3%; 95% CI: 11.7-15.0), and EGFR (9.9%; 95% CI: 5.6-17.0) were the most common involved genetic factors in developing ESCC. This systematic review and meta-analysis revealed that more than 10% of ESCC patients had changes in TP53, CCND1, MDM2, NOTCH1/2/3, KMT2D, CDKN2A, PIK3CA, and FAT1 genes, which can highlight their role in developing ESCC. TP53, CCND1, and MDM2 are the most prevalent, demonstrating 68.6%, 39.3%, and 24.9% of the mutations in ESCC patients.
Identifiants
pubmed: 34611831
doi: 10.1007/s12029-021-00721-y
pii: 10.1007/s12029-021-00721-y
doi:
Substances chimiques
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040-1049Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
International Agency for Research on Cancer. GLOBOCAN 2020, estimated cancer incidence, mortality and prevalence worldwide in 2020. Geneva: World Health Organization, 2020. Available in https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
Murphy G, McCormack V, Abedi-Ardekani B, Arnold M, Camargo M, Dar N, et al. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol. 2017;28(9):2086–93.
doi: 10.1093/annonc/mdx279
pubmed: 28911061
pmcid: 5834011
Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–5.
doi: 10.1016/j.asjsur.2016.10.005
pubmed: 27986415
Kuwano H. Peculiar histopathologic features of esophageal cancer. Surg Today. 1998;28(6):573–5.
doi: 10.1007/s005950050186
pubmed: 9681603
Sewram V, Sitas F, O’Connell D, Myers J. Tobacco and alcohol as risk factors for oesophageal cancer in a high incidence area in South Africa. Cancer Epidemiol. 2016;41:113–21.
doi: 10.1016/j.canep.2016.02.001
pubmed: 26900781
Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: towards targeted therapies. Cell Oncol (Dordr). 2020;43(2):195–209.
doi: 10.1007/s13402-019-00488-2
Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013;61(6):330–5.
doi: 10.1007/s11748-013-0246-0
pubmed: 23568356
Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.
doi: 10.1038/nrdp.2017.48
pubmed: 28748917
pmcid: 6168059
Yazbeck R, Jaenisch SE, Watson DI. From blood to breath: new horizons for esophageal cancer biomarkers. World J Gastroenterol. 2016;22(46):10077–83.
doi: 10.3748/wjg.v22.i46.10077
pubmed: 28028355
pmcid: 5155166
Lam AK. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2000;33(2):71–90.
doi: 10.1016/S1040-8428(99)00054-2
pubmed: 10737369
Seebacher N, Stacy A, Porter G, Merlot A. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38(1):1–39.
doi: 10.1186/s13046-019-1094-2
Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2018;154(2):360–73.
doi: 10.1053/j.gastro.2017.08.023
pubmed: 28823862
He F, Liu C, Zhang R, Hao Z, Li Y, Zhang N, et al. Association between the glutathione-S-transferase T1 null genotype and esophageal cancer susceptibility: a meta-analysis involving 11,163 subjects. Oncotarget. 2018;9(19):15111–21.
doi: 10.18632/oncotarget.24534
pubmed: 29599931
pmcid: 5871102
Kumar P, Rai V. MTHFR C677T polymorphism and risk of esophageal cancer: an updated meta-analysis. Egyptian Journal of Medical Human Genetics. 2018;19(4):273–84.
doi: 10.1016/j.ejmhg.2018.04.003
Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478–86.
doi: 10.1038/ng.2591
pubmed: 23525077
pmcid: 3678719
Cheng C, Cui H, Zhang L, Jia Z, Song B, Wang F, et al. Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience. 2016;5:1.
doi: 10.1186/s13742-015-0107-0
pubmed: 26759717
pmcid: 4709967
Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012;2(10):899–905.
doi: 10.1158/2159-8290.CD-12-0189
pubmed: 22877736
pmcid: 3473124
Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118(5):1173–80.
doi: 10.1002/ijc.21454
pubmed: 16161046
Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007;21(21):2788–803.
doi: 10.1101/gad.1544507
pubmed: 17974918
pmcid: 2045132
Wang Q, Zhu H, Xiao Z, Zhang W, Liu X, Zhang X, et al. Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma. World J Surg Oncol. 2013;11:278.
doi: 10.1186/1477-7819-11-278
pubmed: 24131756
pmcid: 4016601
Xing EP, Yang GY, Wang LD, Shi ST, Yang CS. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res. 1999;5(5):1231–40.
pubmed: 10353761
Taghavi N, Biramijamal F, Sotoudeh M, Khademi H, Malekzadeh R, Moaven O, et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer. 2010;10:138.
doi: 10.1186/1471-2407-10-138
pubmed: 20388212
pmcid: 2868052
Kuwabara T, Hiyama T, Tanaka S, Yoshihara M, Arihiro K, Chayama K. Genetic pathways of multiple esophageal squamous cell carcinomas. Oncol Rep. 2011;25(2):453–9.
pubmed: 21165583
Wang MT, Chen G, An SJ, Chen ZH, Huang ZM, Xiao P, et al. Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2012;25(7):664–70.
doi: 10.1111/j.1442-2050.2011.01291.x
pubmed: 22150974
Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 2013;19(9):2451–9.
doi: 10.1158/1078-0432.CCR-12-3559
pubmed: 23532889
Gen Y, Yasui K, Zen Y, Zen K, Dohi O, Endo M, et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2010;202(2):82–93.
doi: 10.1016/j.cancergencyto.2010.01.023
pubmed: 20875870
Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014 May;46(5):467-73.
Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–5.
doi: 10.1038/nature13176
pubmed: 24670651
Cheng C, Zhou Y, Li H, Xiong T, Li S, Bi Y, et al. Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am J Hum Genet. 2016;98(2):256–74.
doi: 10.1016/j.ajhg.2015.12.013
pubmed: 26833333
pmcid: 4746371
Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y, et al. Genomic Landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150(5):1171–82.
doi: 10.1053/j.gastro.2016.01.035
pubmed: 26873401
DiMaio MA, Kwok S, Montgomery KD, Lowe AW, Pai RK. Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. Hum Pathol. 2012;43(11):1799–807.
doi: 10.1016/j.humpath.2012.03.019
pubmed: 22748473
pmcid: 3465493
Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, et al. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. JCI Insight. 2016;1(16):e88755.
Chang J, Tan W, Ling Z, Xi R, Shao M, Chen M. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun. 2017 May 26;8:15290.
Dai W, Ko JMY, Choi SSA, Yu Z, Ning L, Zheng H, et al. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma. J Pathol. 2017;242(4):500–10.
Visser E, Franken IA, Brosens LA, Ruurda JP, van Hillegersberg R. Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget. 2017;8(3):5566–77.
doi: 10.18632/oncotarget.13328
pubmed: 27852047
Forghanifard MM, Moaven O, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol. 2012;19(3):743–9.
doi: 10.1245/s10434-011-2074-8
pubmed: 22006371